BLA 761258 · Akeso Biopharma
Penpulimab-Kcqx
Penpulimab-Kcqx · Intravenous
NovelBreakthrough therapyOrphanCDER novel approval, Apr 23, 2025: In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Apr 23, 2025
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
79
6 Phase 3, 20 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Penpulimab" as an intervention, any sponsor and status, largest first.
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLPivotal-lookingNot yet recruiting
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT06516978 · 528 participants (planned) · Start Oct 1, 2024 · Primary completion Oct 1, 2028
Drug: Polatuzumab vedotin; Rituximab and 9 more · For: Diffuse Large B Cell Lymphoma
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.Pivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05862337 · 480 participants (planned) · Start May 10, 2023 · Primary completion Aug 2024
Drug: Anlotinib hydrochloride capsules, Penpulimab injection; Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo · For: Hepatocellular Carcinoma
Sites: Bengbu, China; Hefei, China; Beijing, China · 67 sites in all
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaPivotal-lookingActive, not recruiting
AkesoIndustry
NCT04974398 · 296 participants · Start Aug 16, 2021 · Primary completion Feb 23, 2026
Drug: Penpulimab; placebo · For: Nasopharyngeal Carcinoma
Sites: Duarte, California; Atlanta, Georgia; Ann Arbor, Michigan · 56 sites in all
- Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue SarcomaPivotal-lookingNot yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07612098 · 274 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 31, 2031
Drug: Anlotinib; Penpulimab · For: Soft Tissue Sarcoma (STS)
Sites: Beijing, China
- AK129 Combination Therapy for Advanced Solid TumorsPivotal-lookingRecruiting
AkesoIndustry
NCT06943820 · 230 participants (planned) · Start May 21, 2025 · Primary completion Dec 2026
Drug: AK129(dose 1); Pemetrexed and 12 more · For: Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal Adenocarcinoma and 1 more
Sites: Shenyang, China
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06767800 · 204 participants (planned) · Start Nov 21, 2024 · Primary completion Sep 2026
Drug: TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy; TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy and 1 more · For: Gastroesophageal Adenocarcinoma
Sites: Fuyang, China; Lu'an, China; Maanshan, China · 39 sites in all
- Efficacy and Safety of Penpulimab Combined With Anlotinib and ChemotherapyPivotal-lookingRecruiting
Xijing HospitalAcademic, hospital or other
NCT06586242 · 194 participants (planned) · Start Apr 3, 2023 · Primary completion Apr 2025
Drug: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin · For: Esophageal Cancer
Sites: Xi'an, China
- Clinical Studies for the Treatment of Advanced Solid TumorsPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06825494 · 194 participants (planned) · Start Apr 8, 2025 · Primary completion Mar 2026
Drug: LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine; Tislelizumab+Oxaliplatin+Capecitabine and 3 more · For: Advanced Solid Tumor
Sites: Hefei, China; Beijing, China; Fuzhou, China · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
Zhong H, Sun S, Chen J, et al. · Lancet Respir Med 2024 · Randomized Controlled Trial, Multicenter Study
- Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.
Zhou J, Bai L, Luo J, et al. · Lancet Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial.
Sha H, Tong F, Ni J, et al. · Signal Transduct Target Ther 2024 · Clinical Trial, Phase II, Multicenter Study
- Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis.
Liu N, Zhang B, He J, et al. · Front Immunol 2025 · Network Meta-Analysis, Systematic Review
- Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.
Chen X, Wang W, Zou Q, et al. · Signal Transduct Target Ther 2024 · Clinical Trial, Phase II, Multicenter Study
- Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer.
Xu Q, Deng Z, Liu J, et al. · Cancer Discov 2026 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Akeso Biopharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.